Aelan Cell Technologies Adds Human Embryonic Stem Cell Expert Meenakshi Gaur, Ph.D. To Stem Cell Clinical Program

Meenakshi Gaur, Ph.D is the Director of Research and Development of the Stem Cell Program at Aelan Cell Technologies.

(Click here for details)
Meenakshi Gaur, Ph.D is the Director of Research and Development of the Stem Cell Program at Aelan Cell Technologies.
SAN FRANCISCO, CA--(Marketwired - September 11, 2015) - Aelan Cell Technologies announced today the addition of Meenakshi Gaur, Ph.D. to their stem cell clinical program. Dr. Gaur will serve as the Director of Research and Development of the Stem Cell Program, leading a research team that will develop technology aimed at rejuvenation of human mesenchymal stem cells for clinical applications.

"Dr. Gaur is a terrific addition to the world-class scientific team we are building, one with the knowledge and experience to deepen our understanding of stem cells as well as expand and diversify our portfolio," said Dr. Victoria Lunyak, President and Chief Executive Officer at Aelan.

Chester Aldridge, CEO of US Equity Holdings and the Chair of Aelan's Board of Directors, added, "Meenakshi's extensive academic and biotechnology research background in the stem cell field will be invaluable to Aelan as we continue to advance our research and development pipeline."

Dr. Gaur most recently worked as the Director of Cell and Molecular Biology at MandalMed, Inc. in San Francisco, where she led complex research projects using primary cells and stem cells to create bioreactors and led product development in collaboration with stem cell researchers at Stanford University. Previous to that, she served in several different capacities as a senior scientist and researcher at the University of California, San Francisco (UCSF), studying human embryonic stem cells (hESCs). She worked alongside pioneers in the field and gained significant experience working with primary cells, bone marrow cells, platelets and hESCs, leading to her appointment to the cardiology division, Department of Medicine at UCSF.

"I've had the pleasure of knowing Meenakshi when she was in my collaborator's lab at UCSF, and subsequently working with her directly in a fruitful collaboration when she was at MandalMed," said Matthew L. Springer, Ph.D., Professor of Medicine at UCSF. "Her talent and tenacity were instrumental in her successes at UCSF with the development of human embryonic stem cell technologies for cardiac therapies. Bringing Meenakshi on board is definitely a great move for Aelan."

Dr. Gaur earned her Master's and Ph.D. in biochemistry at the Indian Institute of Technology and completed postdoctoral training at the University of California, San Francisco.

About Aelan Cell Technologies:

Aelan Cell Technologies is a San Francisco startup engaged in the research, discovery, development and commercialization of innovative biomedical technologies for the advancement of human health and longevity. With a growing intellectual property portfolio of disruptive technologies and medical tools, Aelan has assembled an experienced team -- bringing together scientific and business expertise -- to successfully lead its products through each phase of development. 


Contact:
Greg D'Agostino
617.695.0369 office
617.388.6477 cell
 

Sponsored by GenScript

Accelerate Biologics, Gene and Cell Therapy Product Development partnering with GenScript ProBio

GenScript ProBio is the bio-pharmaceutical CDMO segment of the world’s leading biotech company GenScript, proactively providing end-to-end service from drug discovery to commercialization with professional solutions and efficient processes to accelerate drug development for customers.

Suggested Articles

While the biotech IPO market booms, it can look like going public is easy. But the right strategy, syndicate and aftermarket are still important.

Gene therapy pioneer Jim Wilson and the University of Pennsylvania are teaming up with Regeneron to help deliver its COVID antibody intransally.

Forty percent of PK deficiency patients on mitapivat had hemoglobalin responses, compared to 0% in the placebo group.